ReviewOncogene2025
Immunometabolism of regulatory T cells in cancer.
Abstract readReview
In one paragraph
Review in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Mitochondrial metabolism and PD-1 blockade: mechanisms and therapeutic opportunities in cancer immunotherapy.Molecular biology reports · 2026Review
- TALDO1 promotes lipid metabolic reprogramming and immunosuppressive microenvironment remodelling in hepatocellular carcinoma.Clinical and translational medicine · 2026Article
- The Glucose Transporter GLUT3 Controls Regulatory T Cell Function.European journal of immunology · 2026Article
- Targeting the cancer metabolism-immunity interface: update and perspectives.Experimental hematology & oncology · 2026Review
- Tumor-adapted regulatory T cells: Molecular reprogramming, immune suppression, and therapeutic targeting in cancer.Molecular biology reports · 2026Review
- Pulsed photobiomodulation reprograms the tumor immune microenvironment to restore local T cell-mediated antitumor immunity.iScience · 2026Article
- From energy metabolic homeostasis to immune remodeling: the role and therapeutic potential of STING signaling in the tumor microenvironment.Cell communication and signaling : CCS · 2026Review
- Metabolic reprogramming of Th17/Treg imbalance in autoimmune thyroid diseases.Cell communication and signaling : CCS · 2026Review
- Identification of novel molecular subtypes in ovarian cancerThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026Article
- Applications of single-cell transcriptomics: updated insights in endometrial cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- T-Cell Immunity and Lung Cancer.Respirology (Carlton, Vic.) · 2026Review
- Targeting metabolic reprogramming to enhance adoptive immunotherapy: emerging mechanisms and translational perspectives.Journal of translational medicine · 2026Review
- A New Complexity Layer: DNA Methylation and the Predictive Impact of Epigenetic Tests.International journal of molecular sciences · 2026Review
- Regulatory T Cell Heterogeneity in the Steady State and Tumor.Immune network · 2026Review
- Metabolic adaptation in CD4Nature immunology · 2026Article
- Regulatory T cells in the breast cancer tumor microenvironment: new mechanisms, potential therapeutic strategies and future perspectives.American journal of cancer research · 2026Review
- Colorectal cancer liver metastasis: immunosuppressive microenvironment, signaling pathways, and emerging therapeutic strategies.Frontiers in immunology · 2026Review
- Redox-driven mitochondrial DNA stress in hepatocellular carcinoma: innate immune remodelling, tumour immune escape, and immunotherapy implications.Frontiers in immunology · 2026Review
- Dynamic Metabolic States in TNBC: Orchestrating Spatiotemporal Adaptation and Therapy.Oncology research · 2026Review
- The dysregulation of the immune microenvironment during endometrial intraepithelial neoplasia serves as a marker of endometrial carcinogenesis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Jordy SaraviaDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-2691-501X
Hongbo ChiDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA. hongbo.chi@stjude.org.ORCID http://orcid.org/0000-0002-9997-2496
Funding
Integrating systems immunology with immunometabolism and cancer immunityR35CA253188 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2021 to 2026
$6.0MRegulation of TH17 plasticity and stemness by mTORC1R01AI131703 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2018 to 2026
$4.1MTranscriptional and metabolic heterogeneity in T cell differentiationR01AI140761 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2018 to 2026
$3.9MMetabolic checkpoint in dendritic cell subsets and adaptive immunityR37AI105887 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2019 to 2026
$3.6MBidirectional signaling in T cell differentiationR01AI150241 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi · 2019 to 2026
$3.3MEnabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunologyU01CA281868 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Hongbo Chi, Jiyang Yu · 2023 to 2026
$3.2MNutrient sensing and lysosomal signaling in regulatory T cells and immune toleranceR01AI150514 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHI, HONGBO · 2019 to 2023
$2.2MMetabolic checkpoint in TH17 cell differentiationR01AI105887 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHI, HONGBO · 2014 to 2018
$2.2MNCI NIH HHS R35 CA253188NCI NIH HHS U01 CA281868NIAID NIH HHS R01 AI105887NIAID NIH HHS R01 AI131703NIAID NIH HHS R01 AI140761NIAID NIH HHS R01 AI150241NIAID NIH HHS R01 AI150514NIAID NIH HHS R37 AI105887U.S. Department of Health & Human Services | National Institutes of Health (NIH) AI105887U.S. Department of Health & Human Services | National Institutes of Health (NIH) AI131703U.S. Department of Health & Human Services | National Institutes of Health (NIH) AI140761U.S. Department of Health & Human Services | National Institutes of Health (NIH) AI150241U.S. Department of Health & Human Services | National Institutes of Health (NIH) AI150514U.S. Department of Health & Human Services | National Institutes of Health (NIH) CA253188U.S. Department of Health & Human Services | National Institutes of Health (NIH) CA281868
Abstract
Regulatory T (T
Indexed as
NeoplasmsT-Lymphocytes, RegulatoryAnimalsHumansImmunotherapyTumor Microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.